181 related articles for article (PubMed ID: 23296214)
1. Serum sclerostin in alcoholics: a pilot study.
González-Reimers E; Martín-González C; de la Vega-Prieto MJ; Pelazas-González R; Fernández-Rodríguez C; López-Prieto J; Alvisa-Negrín J; Santolaria-Fernández F
Alcohol Alcohol; 2013; 48(3):278-82. PubMed ID: 23296214
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
[TBL] [Abstract][Full Text] [Related]
3. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.
Neumann T; Hofbauer LC; Rauner M; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Hamann C; Sämann A
Clin Endocrinol (Oxf); 2014 May; 80(5):649-55. PubMed ID: 24237244
[TBL] [Abstract][Full Text] [Related]
4. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
Kaji H; Imanishi Y; Sugimoto T; Seino S
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin and DKK1 in primary hyperparathyroidism.
Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
[TBL] [Abstract][Full Text] [Related]
10. [Serum sclerostin levels and metabolic bone diseases].
Yamauchi M; Sugimoto T
Clin Calcium; 2013 Jun; 23(6):877-83. PubMed ID: 23719501
[TBL] [Abstract][Full Text] [Related]
11. Serum sclerostin in hepatitis C virus infected patients.
González-Reimers E; López-Prieto J; Pelazas-González R; Alemán-Valls MR; José de la Vega-Prieto M; Jorge-Ripper C; Durán-Castellón MC; Santolaria-Fernández F
J Bone Metab; 2014 Feb; 21(1):69-75. PubMed ID: 24707469
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
[TBL] [Abstract][Full Text] [Related]
14. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.
Amrein K; Amrein S; Drexler C; Dimai HP; Dobnig H; Pfeifer K; Tomaschitz A; Pieber TR; Fahrleitner-Pammer A
J Clin Endocrinol Metab; 2012 Jan; 97(1):148-54. PubMed ID: 21994959
[TBL] [Abstract][Full Text] [Related]
16. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin blood levels before and after kidney transplantation.
Bonani M; Rodriguez D; Fehr T; Mohebbi N; Brockmann J; Blum M; Graf N; Frey D; Wüthrich RP
Kidney Blood Press Res; 2014; 39(4):230-9. PubMed ID: 25118597
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of osteopenia in chronic alcoholics.
González-Reimers E; Alvisa-Negrín J; Santolaria-Fernández F; Ros-Vilamajó R; Martín-González MC; Hernández-Betancor I; García-Valdecasas-Campelo E; González-Díaz A
Alcohol; 2011 May; 45(3):227-38. PubMed ID: 21051177
[TBL] [Abstract][Full Text] [Related]
19. Increased serum sclerostin in postoperative biliary atresia.
Honsawek S; Udomsinprasert W; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Poovorawan Y
Clin Chim Acta; 2015 Mar; 442():136-40. PubMed ID: 25659290
[TBL] [Abstract][Full Text] [Related]
20. Determinants of serum sclerostin in healthy pre- and postmenopausal women.
Ardawi MS; Al-Kadi HA; Rouzi AA; Qari MH
J Bone Miner Res; 2011 Dec; 26(12):2812-22. PubMed ID: 21812027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]